论文部分内容阅读
目的:观察口服普萘洛尔治疗婴幼儿肝脏血管瘤的疗效。方法:17例年龄15 d~11个月的多发性血管瘤患儿经彩色B超、CT、MRI检测诊断为肝脏血管瘤,其中女14例,男3例。所有患儿予以口服普萘洛尔治疗,每日维持剂量2 mg/kg,至少维持6个月,定期复诊,随访观察疗效。结果:17例患儿用药6个月后肝脏血管瘤均明显好转,B超提示结节较治疗前明显缩小,直径由2~44 mm缩小至0~20 mm,其中8例患儿皮肤血管瘤较治疗前明显缩小,颜色变浅。所有患儿用药过程中心电图、血压、血生化等检查均未出现明显异常,停药后病情均未出现反复。结论:普萘洛尔治疗婴幼儿肝脏血管瘤疗效确切且不良反应小,可作为一线治疗药物。
Objective: To observe the efficacy of oral propranolol in the treatment of infantile hemangiomas. Methods: Seventeen children with multiple hemangiomas aged 15 days to 11 months were diagnosed as hepatic hemangiomas by color B-scan, CT and MRI, including 14 females and 3 males. All children were treated with propranolol orally. The daily dose of 2 mg / kg was maintained for at least 6 months. Regular follow-up and follow-up were observed. Results: Seventeen children with hepatic hemangiomas were significantly improved after 6 months of treatment. B - ultrasound showed that the nodules were significantly reduced compared with that before treatment, and the diameter was reduced from 2 to 44 mm to 0 to 20 mm. Among them, 8 cases had hemangiomas Significantly smaller than before treatment, lighter color. All children during medication ECG, blood pressure, blood biochemistry and other tests showed no significant abnormalities after stopping the disease were not repeated. CONCLUSIONS: Propranolol is effective in treating liver and hepatic hemangiomas in infants and young children with small adverse reactions and can be used as first-line treatment.